|会社名||Exelixis Inc （エクセリクス）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Commercial Physical_Biological Resarch|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 エクセチクス（Exelixis Inc.）は癌の低分子療法の開発に取り組むバイオ企業。同社はcabozantinib（カボザンチニブ）（XL184）に資源を投入し、それの開発を集中する。同社は他の化合物製品も有する。カボザンチニブは臨床開発段階にあるMETの阻害剤で、複数の癌の適応症を包含する開発プログラムで査定される。カボザンチニブの臨床プログラムは転移性去勢抵抗性前立腺癌（CRPC）と甲状腺髄様癌の治療に集中し、他のタイプの腫瘍の査定も含む。カボザンチニブは腫瘍の増殖、血管侵入および/または転移のキードライバーであるタンパク質のMET、血管内皮増殖因子受容体２（VEGFR2）、及びトランスフェクション中の再構成（RET）を抑制する。 エクセリクスは米国のバイオ医薬品メ―カ―。主にがん治療のための小分子治療薬の開発、製品化に従事。進行性・転移性甲状腺髄様癌の治療薬「COMETRIO」(カボザンチニブ)に焦点を当てた臨床活動を行う。同社は1994年に設立され、カリフォルニア州サウスサンフランシスコに本社を置く。 Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.|
|本社所在地||1851 Harbor Bay Parkway Alameda CA 94502 USA|
|代表者氏名||Stelios Papadopoulos Stelios Papadopoulos|
|代表者役職名||Independent Chairman of the Board Co-Founder|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Exelixis Inc. revenues increased from $179.9M to $398.5M. Net income increased from $34.4M to $203.4M. Revenues reflect Net product revenues increase of 79% to $280.1M Collaboration revenues increase from $23M to $118.3M. Net income benefited from Interest expense decrease from $8.7M (expense) to $0K Interest Income increase of 71% to $4.6M (income).|
Exelixis: Overdependence On Cabozantinib (NASDAQ:EXEL) 2022/08/03 10:46:31 Seeking Alpha
Exelixis stock has done quite well for me in the past few months. Check out why I intend to keep holding EXEL stock for a few more quarters.
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 2022/07/26 20:05:00 Exelixis
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 26, 2022-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 after the markets close. At 5:00 p.m.
Exelixis PT Raised to $32 at Piper Sandler 2022/07/26 10:23:14 Investing.com
7 Undervalued Biotech Stocks to Buy Before They Boom 2022/07/25 14:43:22 InvestorPlace
With fears of a global recession rising, it’s natural that investors have turned their back on growth-intensive names. However, this backdrop has also yielded compelling undervalued biotech stocks to buy. While very few sectors have been spared the damage stemming from soaring inflation, geopolitical instability and supply chain disruptions, the biological sciences arena offers long-term relevance. Mainly, it doesn’t matter whether a recession is about to capsize our economy or not. Since humans remain vulnerable to various diseases and medical conditions, it’s imperative that researchers continue to move forward. Therefore, undervalued biotech stocks to buy command significant interest because at some point, they have the potential to rise substantially higher. The 7 Best Funds For Retirees To be fair, the underlying sector is volatile. And many times, a company sheds basis points in the equities market for a reason — often not a good one. Still, if you have some spare funds for speculation, these undervalued stocks to buy could offer significant bang for your buck.
1 Reason to Buy Exelixis Stock, and 1 Reason to Sell 2022/07/22 14:15:00 The Motley Fool
Some say Exelixis is a one-trick pony -- but it is a pretty good trick.
How Did Hedge Funds’ Exelixis, Inc. (EXEL) Bets Fare? 2022/02/07 20:28:41 Insider Monkey
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Exelixis (EXEL) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference 2022/01/24 19:25:55 Seeking Alpha
Hot Stocks: LULU, EXEL dip on guidance; TLRY rallies on earnings; MOLN pops on COVID clinical data 2022/01/10 13:33:12 Seeking Alpha
Corporate results, both actual and predicted, spurred trading in Monday''s pre-market action
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022 2022/01/04 21:05:00 Kwhen Finance
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer 2022/01/04 13:00:00 Kwhen Finance
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer 2021/11/09 13:00:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is now completed for CONTACT-01, the global, phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. Patients with advanced non-small cell lung cancer urgently need new treatment opti
Credit Suisse AG Sells 46,493 Shares of Exelixis, Inc. (NASDAQ:EXEL) 2021/11/08 13:12:41 Dakota Financial News
Credit Suisse AG trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 9.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 426,675 shares of the biotechnology companys stock after selling 46,493 shares during the period. Credit Suisse AGs holdings in Exelixis were worth $7,775,000 
Exelixis (NASDAQ:EXEL) Downgraded by TheStreet to C 2021/11/08 06:18:41 Dakota Financial News
TheStreet downgraded shares of Exelixis (NASDAQ:EXEL) from a b- rating to a c rating in a report issued on Thursday morning, TheStreetRatingsTable reports. Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada decreased their price target on shares of Exelixis from $32.00 to $31.00 and set an outperform 
TheStreet Lowers Exelixis (NASDAQ:EXEL) to C 2021/11/06 14:54:42 Transcript Daily
Exelixis (NASDAQ:EXEL) was downgraded by analysts at TheStreet from a b- rating to a c rating in a research report issued to clients and investors on Thursday, TheStreetRatingsTable reports. A number of other brokerages have also recently commented on EXEL. Zacks Investment Research raised shares of Exelixis from a hold rating to a strong-buy rating 
Exelixis (NASDAQ:EXEL) Posts Earnings Results, Misses Estimates By $0.07 EPS 2021/11/06 04:00:41 Transcript Daily
Exelixis (NASDAQ:EXEL) released its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts consensus estimates of $0.19 by ($0.07), MarketWatch Earnings reports. Exelixis had a net margin of 13.10% and a return on equity of 8.45%. During the same quarter in the prior year, the business 
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 エクセリクス EXEL Exelixis Inc.）